Mr. Russell Starr reports

VECTOR SCIENCE AND THERAPEUTICS CORP. APPOINTS ANGUS JACKSON AS MANAGING DIRECTOR OF CORPORATE DEVELOPMENT

Vector Science and Therapeutics Corp. has appointed Angus Jackson as managing director of corporate development. In this role, Mr. Jackson will assist in the company's organic and lead the inorganic growth initiatives, with responsibility for advancing strategic partnerships, evaluating acquisition and investment opportunities, and supporting the company's long-term commercial and corporate development strategy.

Mr. Jackson brings a multidisciplinary background spanning investment banking, corporate law, business strategy and operating experience in the life sciences sector. Most recently, he served as an investment banker at Outcome Capital, a Boston-based boutique investment bank focused on the health care and life sciences industries. At Outcome Capital, he advised companies across pharmaceuticals, pharmaceutical services, medical technology and health care services on mergers and acquisitions, capital raising, and strategic transactions.

Prior to his investment banking career, Mr. Jackson held corporate development and operating responsibilities at a family owned contract manufacturing business serving the pharmaceutical and life sciences industries, where he was involved in strategic initiatives and acquisitions. Vector believes his combination of transaction execution experience and direct operating exposure positions him to help the company pursue growth opportunities across its business and technology platforms.

Mr. Jackson holds a master of business administration from the University of Virginia Darden School of Business, a Juris Doctor from the University of Georgia School of Law, and a master of laws (LLM) from Duke University School of Law, with a focus on law and entrepreneurship. His academic and professional background combines financial analysis, transaction structuring, corporate strategy, entrepreneurship and legal expertise.

Role and priorities

In his new role, Mr. Jackson will focus on identifying and executing opportunities to accelerate Vector's growth, including commercial expansion, strategic alliances, business development initiatives, and selective mergers and acquisitions. He will also work with company leadership to evaluate opportunities that complement Vector's existing capabilities and support the development and commercialization of its therapeutic delivery technologies, medical devices and peptide-related offerings.

"Disciplined corporate development is essential to turning Vector's technology platforms into lasting commercial value," said Tommy Thompson, chairman of Vector Science and Therapeutics and former U.S. Secretary of Health and Human Services. "Angus's background in health care investment banking, law, and pharmaceutical manufacturing gives the company the expertise to evaluate and execute strategic opportunities with rigor, and we are pleased to welcome him to the team."

"Angus brings a rare combination of transaction experience and hands-on operating knowledge of pharmaceutical manufacturing, which is exactly what Vector needs as we scale," said Russell Starr, president of Vector Science and Therapeutics. "As we evaluate partnerships and acquisitions that complement our delivery technologies and peptide platform, his ability to identify, structure and execute the right opportunities will be an important asset to the company and our shareholders."

"I am excited to join Vector at an important stage in the company's development," said Angus Jackson, managing director of corporate development. "Vector has an opportunity to build on its existing technology platforms, deepen strategic partnerships and pursue new avenues for commercial growth. I look forward to working with the team to execute a disciplined growth strategy that combines organic expansion with targeted strategic transactions and partnerships."

About Vector Science and Therapeutics Corp.

Vector Science and Therapeutics is a medical technology company advancing drug delivery technology and pharma-grade peptide manufacturing for the sports medicine, regenerative medicine and pain management markets. Vector's peptides are pharma-grade, not research-grade: they are manufactured under cGMP (current good manufacturing practice), FDA (Food and Drug Administration) and ISO-compliant conditions, Rx-labelled and sold directly to physicians for physician use, rather than distributed through the research-only channels associated with research-grade material. The company's product and intellectual property portfolio is focused on advanced transdermal delivery, precision catheter systems, localized pain management, pancreatic oncology and smart wound care. Vector is headquartered in Mequon, Wis.

We seek Safe Harbor.